TYPE OF ARTICLE: ORIGINAL ARTICLE ROLE OF CYTOKERATIN BIOMARKERS IN BREAST CARCINOMA
DOI:
https://doi.org/10.22159/ajpcr.2016.v9i6.14413Abstract
Â
ABSTRACT:
Objective:Breast cancer comprises different biological subtypes having varied spectrum of clinical and pathological features with different prognostic and therapeutic implications. This study aimed at the identification of patients on the basis of cancer biomarkers and various clinicopathological parameters.
Methods: Fresh paraffin embedded tissue block sample of three hundred fifty patients of breast carcinoma were collected during 2011-2014, from the Pathology department, Pt. B.D Sharma University of Heath Sciences Rohtak, Haryana and studied in detail to determine the correlation between hormone receptor status /cytokeratin (CK) expression along with clinicopathologicalfactors.Theimmunohistochemical assay of three hundred fifty patients of breast cancer was performed.Maximum number of patients (35%) were found in the age group of <40 years. Most of the patients were observed with the grade I (59%), tumor size 2-4.9cm (45%), <4 positive lymph node status for metastasis andinfiltrate ductal carcinoma type (93%).Triple positive and triple negative breast cancer types were studiedto identify the basal and luminal phenotypes on the basis of markers CK5, 14 and CK8/18 expression.Results:The expression of CK5 &14 was found to be significantly associated with tumor grade (P=0.001 and P=0.0001), tumor size (P= 0.001) respectively.Whereas CK8/18 expression did not reveal any significant association with tumor grade,size, lymph node status and histological type of breast carcinoma.
Conclusion:In conclusion the prognostic and therapeutic value of research work would be examined and validated further on larger number of samples.
Keywords: Breast carcinoma, biomarkers, clinicopathological factors, Cytokeratin, hormone receptor
Â
Downloads
References
REFERENCES
WHO. Cancer Pain Relief: With a Guide to Opioid Availability. 2nd ed.
Geneva: World Health Organization; 1996. Available from: http://www.
apps.who.int/iris/bitstream/10665/37896/1/9241544821.pdf.
GLOBOCAN. Cancer Fact Sheet. Breast Cancer Incidence and
Mortality Worldwide in; 2008. Available from: http://www.globocan.
iarc.fr/factsheets/cancers/breast.asp. [Last accessed on 2011 Jul 20].
Ellis IO, Galea M, Broughton N, Locker A, Blamey RW, Elston CW.
Pathological prognostic factors in breast cancer. II. Histological type.
Relationship with survival in a large study with long-term follow-up.
Histopathology 1992;20(6):479-89.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS,
Rees CA, et al. Molecular portraits of human breast tumours. Nature
;406(6797):747-52.
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al.
Repeated observation of breast tumor subtypes in independent gene
expression data sets. Proc Natl Acad Sci U S A 2003;100(14):8418-23.
De Andrade TS, Mosegui GB, Miranda ES, Vianna CM. Trastuzumab
in metastatic breast cancer: Systematic review of cost-effectiveness
analyses. Int J Pharm Pharm Sci 2015;7(7):47-56.
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, et al.
Basal-like and triple-negative breast cancers: A critical review with an
emphasis on the implications for pathologists and oncologists. Mod
Pathol 2011;24(2):157-67.
Gilbert S, Loranger A, Daigle N, Marceau N. Simple epithelium
keratins 8 and 18 provide resistance to Fas-mediated apoptosis. The
protection occurs through a receptor-targeting modulation. J Cell Biol
;154(4):763-73.
Galarneau L, Loranger A, Gilbert S, Marceau N. Keratins modulate
hepatic cell adhesion, size and G1/S transition. Exp Cell Res
;313(1):179-94.
Coulombe PA, Omary MB. ‘Hard’ and ‘soft’ principles defining the
structure, function and regulation of keratin intermediate filaments.
Curr Opin Cell Biol 2002;14(1):110-22.
Ku NO, Michie S, Resurreccion EZ, Broome RL, Omary MB. Keratin
binding to 14-3-3 proteins modulates keratin filaments and hepatocyte
mitotic progression. Proc Natl Acad Sci U S A 2002;99(7):4373-8.
Bloom HJ, Richardson WW. Histological grading and prognosis in
breast cancer; A study of 1409 cases of which 359 have been followed
for 15 years. Br J Cancer 1957;11(3):359-77.
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular
portraits of breast tumors are conserved across microarray platforms.
BMC Genomics 2006;7:96.
Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW,
Robertson JF, et al. Expression of luminal and basal cytokeratins in
human breast carcinoma. J Pathol 2004;203(2):661-71.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K,
et al. Race, breast cancer subtypes, and survival in the Carolina breast
cancer study. JAMA 2006;295(21):2492-502.
Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF,
Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer
;109(1):25-32.
Winter J. Morphological and immunophenotypic analysis of basal-like
carcinoma of the breast. Biosci Horiz 2008;1(1):19-27.
Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K,
Steele D, et al. BRCA1 dysfunction in sporadic basal-like breast cancer.
Oncogene 2007;26(14):2126-32.
Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI,
Moore DT, et al. Phenotypic evaluation of the basal-like subtype of
invasive breast carcinoma. Mod Pathol 2006;19(2):264-71.
Holla SN, Nayak V, Bairy KL, Tripathy A, Holla S. Her-2 gene,
receptors and drug target: A systematic review. Int J Pharm Pharm Sci
;8(4):4-9.
Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA,
et al. Amplification of EMSY, a novel oncogene on 11q13, in
high grade ovarian surface epithelial carcinomas. Gynecol Oncol
;100(2):264-70.
Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification
and molecular forecasting of breast cancer: Ready for clinical
application? J Clin Oncol 2005;23(29):7350-60.
Bland JM, Altman DG. Survival probabilities (the Kaplan-Meier
method). BMJ 1998;317(7172):1572.
Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, Ellis GK, et al.
HER-2 testing in breast cancer using parallel tissue-based methods.
JAMA 2004;291(16):1972-7.
Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK,
et al. Basal-like breast cancer defined by five biomarkers has superior
prognostic value than triple-negative phenotype. Clin Cancer Res
;14(5):1368-76.
Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic
significance of the basal-like subtype of breast cancer: A comparison
with hormone receptor and Her2/neu-overexpressing phenotypes. Hum
Pathol 2006;37(9):1217-26.
Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J,
Gerson N, et al. Computer program to assist in making decisions about
adjuvant therapy for women with early breast cancer. J Clin Oncol
;19(4):980-91.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive
analysis of estrogen receptor (ER)-negative, progesterone receptor
(PR)-negative, and HER2-negative invasive breast cancer, the socalled
triple-negative phenotype: A population-based study from the
California cancer Registry. Cancer 2007;109(9):1721-8.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
